EGFR
MIM.131550 7p12.3-p12.1
Pathology
gene amplification and overexpression
- glioblastoma (34%)
- anaplastic oligodendroglioma
germline mutations
- non-small cell lung cancer predisposition (16258541)
- non-small cell lung cancers
EGFR-inhibitors
- gefitinib inhibits the tyrosine kinase activity of EGFR, the receptor for EGF (epidermal growth factor)
Reviews
Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007 Mar;7(3):169-81. PMID: 17318210
Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 2006 Nov;6(11):876-85. PMID: 17036041
Herbst RS, Fukuoka M, Baselga J. Gefitinib?a novel targeted approach to treating cancer. Nat Rev Cancer. 2004 Dec;4(12):956-65. PMID: 15573117
Carpenter G. The EGF receptor: a nexus for trafficking and signaling. Bioessays. 2000 Aug;22(8):697-707. PMID: 10918300
References
Hijiya N, Miyawaki M, Kawahara K, Akamine S, Tsuji K, Kadota J, Akizuki S, Uchida T, Matsuura K, Tsukamoto Y, Moriyama M. Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. Hum Pathol. 2008 Mar;39(3):316-23. PMID: 18261621
Ch?ng S, Low I, Ng D, Brasch H, Sullivan M, Davis P, Tan ST. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol. 2008 Mar;39(3):344-9. Epub 2007 Nov 28. PMID: 18045646